Works matching IS 13520504 AND DT 2019 AND VI 26 AND IP 8
Results: 12
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 951, doi. 10.1111/jvh.13110
- By:
- Publication type:
- Article
Real‐world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct‐acting antiviral experienced hepatitis C patients.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 980, doi. 10.1111/jvh.13115
- By:
- Publication type:
- Article
Expression of programmed cell death protein 1 and T‐cell immunoglobulin‐ and mucin‐domain‐containing molecule‐3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 942, doi. 10.1111/jvh.13108
- By:
- Publication type:
- Article
HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 1002, doi. 10.1111/jvh.13106
- By:
- Publication type:
- Article
Treatment and monitoring of children with chronic hepatitis C in the Pre‐DAA era: A European survey of 38 paediatric specialists.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 961, doi. 10.1111/jvh.13111
- By:
- Publication type:
- Article
In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 991, doi. 10.1111/jvh.13116
- By:
- Publication type:
- Article
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 1027, doi. 10.1111/jvh.13109
- By:
- Publication type:
- Article
Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 1019, doi. 10.1111/jvh.13114
- By:
- Publication type:
- Article
Hepatitis C virus testing, liver disease assessment and direct‐acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 969, doi. 10.1111/jvh.13112
- By:
- Publication type:
- Article
Maternal HBsAg carriers and adverse pregnancy outcomes: A hospital‐based prospective cohort analysis.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 1011, doi. 10.1111/jvh.13105
- By:
- Publication type:
- Article
Can we stop nucleoside analogues before HBsAg loss?
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 936, doi. 10.1111/jvh.13091
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 933, doi. 10.1111/jvh.12957
- Publication type:
- Article